Target intelligence / Profile preview

Serotonin, Dopamine, and Adrenergic receptors (5-HTR, DR, AR)

Target
5-HTR, DR, AR
Molecular classification
G protein-coupled receptor (GPCR), Receptor
01

Overview

Serotonin, dopamine, and adrenergic receptors are three large families of G protein-coupled receptors that mediate the effects of their respective neurotransmitters—serotonin (5-HT), dopamine (DA), and catecholamines (norepinephrine, epinephrine). Each family comprises multiple receptor subtypes with unique distributions, signaling mechanisms, and physiological effects. These receptors are central targets for drugs used in the management of depression, schizophrenia, hypertension, pain, and other psychiatric, neurological, and cardiovascular disorders. Due to high structural and functional diversity, precise pharmacological intervention at specific subtypes enables tailored therapeutic actions but also poses a challenge for safety and adverse effects.

Other names
5-hydroxytryptamine receptor5-HT receptorDA receptorDR receptorAdrenoceptorAR receptoralpha-adrenergic receptorbeta-adrenergic receptor
02

Mechanism of action

Agonism (activating the receptor). Antagonism (blocking the receptor). Inverse agonism. Modulation of intracellular second messengers (e.g., cAMP via GPCRs). Polypharmacology: simultaneous modulation of multiple receptor systems for synergistic or additive therapeutic effects. Allosteric modulation.

03

Biological functions

Signal transductionNeurotransmissionRegulation of mood, cognition, reward, motor function, cardiovascular function, and smooth muscle activityModulation of hormone secretion
04

Disease associations

DepressionSchizophreniaBipolar disorderAnxiety disordersNeurodegenerative disease (Alzheimer's, Parkinson's, etc.)Cardiovascular diseaseAttention-deficit disordersDrug abuse and addictionOther psychiatric and neurological disorders
05

Safety considerations

Cross-reactivity and off-target effects due to receptor promiscuityCNS side effects: sedation, movement disorders, psychosis, mood changesCardiovascular risks: arrhythmia, hypertension, orthostatic hypotensionSerotonin syndromeDyskinesia, neuroleptic malignant syndrome (dopamine antagonists)Drug-drug interactions due to overlapping mechanisms
06

Interacting drugs

Sumatriptan

16 more in the full profile.

07

Biomarkers

Levels of neurotransmitters (serotonin, dopamine, norepinephrine) in CSF or plasmaReceptor occupancy by PET imaging (especially for antipsychotic drugs)Genetic polymorphisms in receptor subunits (e.g., DRD2, HTR2A)

Beyond the preview

Go deeper on Serotonin, Dopamine, and Adrenergic receptors (5-HTR, DR, AR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serotonin, Dopamine, and Adrenergic receptors (5-HTR, DR, AR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call